34 results about "Wild type mice" patented technology

The invention discloses a novel application of an inhibitor for protein HSD17B13 or coding genes thereof. The novel application provided by the invention particularly means the application of the inhibitor for the protein HSD17B13 or the coding genes thereof in preparation of products for preventing and / or treating fatty liver. Proved by experiments, through immunizing a C57 wild-type mouse by using a recombinant adenovirus carrying an HSD17B13 gene, the condition that the liver of the mouse is subjected to obvious fatty change can be observed, oil red of a slice of the liver is stained and shows the accumulation of a lot of fat, and the content of triglyceride and cholesterol in liver tissues is increased remarkably, so that the HSD17B13 possibly participates in the formation process of fatty liver. The novel application has an important significance in prevention and / or treatment of fatty liver.

The invention provides a construction method of a mouse lung cancer model. The method includes the steps of: S1, taking C57BL / 6J wild-type mice of 6-8 weeks old, performing adaptation for 1-2 weeks, then putting the mice into a main cabinet of an inhalation exposure cabinet for benzopyrene exposure with the condition parameters of: 5d / week, 5-8h / day, a benzopyrene exposure concentration of 9-12microg / m<3>, and stopping feeding of the mice and allowing free drinking during the exposure; and S2, performing exposure for 23-28 weeks, thus obtaining the mouse lung cancer model. The invention belongs to the field of biotechnology. The method provided by the invention causes no artificial damage to the original structure of the lung, also does not cause infection or other interferences, conformsto the actual environmental exposure way of the human body, can better reflect the actual occurrence of lung cancer in the human body, and is beneficial to the development of lung cancer-related therapeutic drugs.

The invention provides a construction method of a mouse model with conditional mTERT overexpression and an application thereof. The construction method comprises the following steps: constructing a targeting vector through a seamless cloning technology, wherein the targeting vector comprises a 3.3 kb 5'homologous arm, a CAG promoter, loxp-stop-loxp, TERT-3XFlag-IRES-EGFP-WPRE-polyA and a 3.3 kb 3'homologous arm; cas9 mRNA, gRNA and the targeting vector are microinjected into fertilized eggs of wild type mice to obtain F0-generation mice, homologous recombination positive F0-generation mice are identified, F1-generation mice are obtained through breeding after backcross, and the F1-generation mice are conditional mTERT overexpressed mouse models. The mouse constructed by the construction method provided by the invention can mate with different Cre tool mice to realize specific overexpression in various tissues, organs and cell types of the whole body. The mouse can be used for modeling various transgenic models for researching embryo and nerve development, senescence, wound repair, tumor occurrence, development and treatment, and the mating of the mouse and a CreERT tool mouse can control the time of TERT overexpression through tamoxifen.

The invention discloses application of TRPV1 in screening or preparing medicines for preventing, relieving and / or treating liver diseases, and belongs to the field of functions and application of genes. According to the application, TRPV1 gene overexpressed and knocked-out C57 / BL mouses are taken as experimental subjects, and through research on an acute liver injury model, a hepatic fibrosis model, a non-alcoholic fatty liver model and an alcoholic fatty liver model, results show that compared with a control group mouse, the TRPV1 gene overexpressed mouse is obviously inhibited in liver injury and obviously improved in liver function; and compared with a wild type mouse, the liver pathological injury of the TRPV1 gene knockout mouse is obviously aggravated, and the liver function is obviously deteriorated. Aiming at the functions of the TRPV1, the expression of the TRPV1 gene can be promoted through a specific agonist or an overexpression system of the TRPV1 so as to interfere with liver diseases such as liver inflammation, liver fibrosis and the like.

The invention relates to the field of inner ear stem cells, in particular to a method for regulating proliferation and differentiation of inner ear stem cells through Rassf2 and application of Rassf2 in hair cell regeneration. The regulation and control method comprises the following steps: 1, detecting expression conditions of Shh or Hippo and Rassf2 in cochlea in a wild type mouse; 2, studying the effect of Shh or Hippo and Rassf2 on proliferation and differentiation of the inner ear stem cells which are separated in a flow mode in an in-vitro experiment; 3, researching the effects of Shh or Hippo and Rassf2 on a living hair cell neomycin injury model. By using the Lgr5-EGFP-CreERT2 tool mouse, the separation of the inner ear stem cells (Lgr5 positive cells) is accurate and a large amount of the inner ear stem cells (Lgr5 positive cells) can be realized, and a relatively good research premise can be achieved: the Lgr5 positive inner ear stem cells of the mouse are sorted. Besides, after the separated inner ear stem cells are subjected to balling and differentiation experiments by researching Shh, Hippo and Rassf2 in an in-vitro experiment, the specific action mechanism of Shh, Hippo and Rassf2 in regulation and control of proliferation and differentiation of the inner ear stem cells and hair cell regeneration can be deeply explored.

The invention discloses application of PSMB8 and a PSMB8 inhibitor to preparation of medicine for treating fatty liver and related diseases. Primary hepatocytes of C57BL / 6 wild type mice and PSMB8 knock-down C57BL / 6 mice are separated; the functions of PSMB8 gene are studied by a palmitate and oleic acid stimulation induced liver cell lipid accumulation model. The result proves that when the PSMB8expression is lowered, the PA+OA stimulation induced primary hepatocyte lipid accumulation is obviously reduced, i.e., the PSMB8 gene can promote the development and progression of fatty liver and related diseases; in an HFHC (high fat and high cholesterol) induced WT mouse fatty liver disease model, PR-957 can obviously inhibit HFHC induced weight increase, white grease increase and liver lipidaccumulation; the development and progression of the fatty liver and related diseases are inhibited. Therefore the PSMB8 provides a target for developing medicine for preventing, relieving and / or treating the fatty liver and related diseases.